93 related articles for article (PubMed ID: 20483614)
21. Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists.
Huang CQ; Wilcoxen KM; Grigoriadis DE; McCarthy JR; Chen C
Bioorg Med Chem Lett; 2004 Aug; 14(15):3943-7. PubMed ID: 15225703
[TBL] [Abstract][Full Text] [Related]
22. Potential CRF1R PET imaging agents: 1-fluoroalkylsubstituted 5-halo-3-(arylamino)pyrazin-2(1H)-ones.
Denhart DJ; Zuev D; Ditta JL; Hartz RA; Ahuja VT; Mattson RJ; Huang H; Mattson GK; Zueva L; Nielsen JM; Kozlowski ES; Lodge NJ; Bronson JJ; Macor JE
Bioorg Med Chem Lett; 2013 Apr; 23(7):2052-5. PubMed ID: 23465610
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, structure-activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists.
Han X; Michne JA; Pin SS; Burris KD; Balanda LA; Fung LK; Fiedler T; Browman KE; Taber MT; Zhang J; Dubowchik GM
Bioorg Med Chem Lett; 2005 Sep; 15(17):3870-3. PubMed ID: 15990298
[TBL] [Abstract][Full Text] [Related]
24. Rational design, synthesis, and structure-activity relationships of aryltriazoles as novel corticotropin-releasing factor-1 receptor antagonists.
Lowe RF; Nelson J; Dang TN; Crowe PD; Pahuja A; McCarthy JR; Grigoriadis DE; Conlon P; Saunders J; Chen C; Szabo T; Chen TK; Bozigian H
J Med Chem; 2005 Mar; 48(5):1540-9. PubMed ID: 15743196
[TBL] [Abstract][Full Text] [Related]
25. Heteroatom-linked indanylpyrazines are corticotropin releasing factor type-1 receptor antagonists.
Corbett JW; Rauckhorst MR; Qian F; Hoffman RL; Knauer CS; Fitzgerald LW
Bioorg Med Chem Lett; 2007 Nov; 17(22):6250-6. PubMed ID: 17888659
[TBL] [Abstract][Full Text] [Related]
26. A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist.
Hartz RA; Ahuja VT; Zhuo X; Mattson RJ; Denhart DJ; Deskus JA; Vrudhula VM; Pan S; Ditta JL; Shu YZ; Grace JE; Lentz KA; Lelas S; Li YW; Molski TF; Krishnananthan S; Wong H; Qian-Cutrone J; Schartman R; Denton R; Lodge NJ; Zaczek R; Macor JE; Bronson JJ
J Med Chem; 2009 Dec; 52(23):7653-68. PubMed ID: 19954247
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of 2,3,5,6-tetrahydro-3H-imidazo[2,1-b] [1,3,5]benzotriazepines and their oxidative ring contraction into 1-(4,5-dihydro-1H-imidazol-2-yl)-1H-benzimidazoles.
Saczewski F; Kobierska E; Tyacke RJ; Hudson AL; Nutt DJ; Gdaniec M
Farmaco; 2005 Feb; 60(2):127-34. PubMed ID: 15752471
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and structure-activity relationship of imidazo[1,2-a]benzimidazoles as corticotropin-releasing factor 1 receptor antagonists.
Han X; Pin SS; Burris K; Fung LK; Huang S; Taber MT; Zhang J; Dubowchik GM
Bioorg Med Chem Lett; 2005 Sep; 15(18):4029-32. PubMed ID: 15982881
[TBL] [Abstract][Full Text] [Related]
29. New class of corticotropin-releasing factor (CRF) antagonists: small peptides having high binding affinity for CRF receptor.
Yamada Y; Mizutani K; Mizusawa Y; Hantani Y; Tanaka M; Tanaka Y; Tomimoto M; Sugawara M; Imai N; Yamada H; Okajima N; Haruta J
J Med Chem; 2004 Feb; 47(5):1075-8. PubMed ID: 14971886
[TBL] [Abstract][Full Text] [Related]
30. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Nakazato A; Kumagai T; Okubo T; Tomisawa K
J Pharmacol Exp Ther; 1999 May; 289(2):926-35. PubMed ID: 10215672
[TBL] [Abstract][Full Text] [Related]
31. Acute and chronic corticotropin-releasing factor 1 receptor blockade inhibits cocaine-induced dopamine release: correlation with dopamine neuron activity.
Lodge DJ; Grace AA
J Pharmacol Exp Ther; 2005 Jul; 314(1):201-6. PubMed ID: 15784652
[TBL] [Abstract][Full Text] [Related]
32. Discovery of a 7-arylaminobenzimidazole series as novel CRF1 receptor antagonists.
Mochizuki M; Kori M; Kono M; Yano T; Sako Y; Tanaka M; Kanzaki N; Gyorkos AC; Corrette CP; Aso K
Bioorg Med Chem; 2016 Oct; 24(19):4675-4691. PubMed ID: 27567079
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and structure-activity relationships of 5-alkylaminolquinolines as a novel series of CRF1 receptor antagonists.
Takeda K; Terauchi T; Shin K; Ino M; Shibata H; Yonaga M
Bioorg Med Chem Lett; 2012 Jul; 22(14):4756-61. PubMed ID: 22683343
[TBL] [Abstract][Full Text] [Related]
34. Corticotropin-releasing hormone receptor antagonists: framework design and synthesis guided by ligand conformational studies.
Hodge CN; Aldrich PE; Wasserman ZR; Fernandez CH; Nemeth GA; Arvanitis A; Cheeseman RS; Chorvat RJ; Ciganek E; Christos TE; Gilligan PJ; Krenitsky P; Scholfield E; Strucely P
J Med Chem; 1999 Mar; 42(5):819-32. PubMed ID: 10072680
[TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.
Guo Z; Tellew JE; Gross RS; Dyck B; Grey J; Haddach M; Kiankarimi M; Lanier M; Li BF; Luo Z; McCarthy JR; Moorjani M; Saunders J; Sullivan R; Zhang X; Zamani-Kord S; Grigoriadis DE; Crowe PD; Chen TK; Williams JP
J Med Chem; 2005 Aug; 48(16):5104-7. PubMed ID: 16078829
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist.
Chen YL; Mansbach RS; Winter SM; Brooks E; Collins J; Corman ML; Dunaiskis AR; Faraci WS; Gallaschun RJ; Schmidt A; Schulz DW
J Med Chem; 1997 May; 40(11):1749-54. PubMed ID: 9171885
[TBL] [Abstract][Full Text] [Related]
37. Synthesis of benzoylpyrimidines as antagonists of the corticotropin-releasing factor-1 receptor.
Webb TR; Moran T; Huang CQ; McCarthy JR; Grigoriadis DE; Chen C
Bioorg Med Chem Lett; 2004 Aug; 14(15):3869-73. PubMed ID: 15225687
[TBL] [Abstract][Full Text] [Related]
38. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
[TBL] [Abstract][Full Text] [Related]
39. Dihydropyridopyrazinones and dihydropteridinones as corticotropin-releasing factor-1 receptor antagonists: structure-activity relationships and computational modeling.
Dzierba CD; Tebben AJ; Wilde RG; Takvorian AG; Rafalski M; Kasireddy-Polam P; Klaczkiewicz JD; Pechulis AD; Davis AL; Sweet MP; Woo AM; Yang Z; Ebeltoft SM; Molski TF; Zhang G; Zaczek RC; Trainor GL; Combs AP; Gilligan PJ
J Med Chem; 2007 May; 50(9):2269-72. PubMed ID: 17402721
[TBL] [Abstract][Full Text] [Related]
40. Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility.
Chen C; Wilcoxen KM; Huang CQ; McCarthy JR; Chen T; Grigoriadis DE
Bioorg Med Chem Lett; 2004 Jul; 14(14):3669-73. PubMed ID: 15203140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
